Myeloid Leukemia, Chronic
|
|
0.740 |
GeneticVariation
|
CLINVAR |
[Correlation between point mutation in ABL kinase and clinical outcome of chronic myeloid leukemia patients].
|
25152116 |
2014 |
Myeloid Leukemia, Chronic
|
|
0.740 |
GeneticVariation
|
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
Myeloid Leukemia, Chronic
|
|
0.740 |
GeneticVariation
|
CLINVAR |
Detection of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on imatinib.
|
23676790 |
2013 |
Myeloid Leukemia, Chronic
|
|
0.740 |
GeneticVariation
|
CLINVAR |
Detection of ABL1 kinase mutations in Philadelphia-positive patients exhibiting an inadequate molecular response using restriction fragment mass polymorphism and its clinical significance: a single-center experience in Korea.
|
23575252 |
2013 |
Myeloid Leukemia, Chronic
|
|
0.740 |
GeneticVariation
|
BEFREE |
Dasatinib overrides imatinib resistance mediated by the F359I residue mutation in two patients with chronic myeloid leukemia.
|
22094354 |
2012 |
Myeloid Leukemia, Chronic
|
|
0.740 |
GeneticVariation
|
CLINVAR |
BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.
|
21562040 |
2011 |
Myeloid Leukemia, Chronic
|
|
0.740 |
GeneticVariation
|
CLINVAR |
BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.
|
21562040 |
2011 |
Myeloid Leukemia, Chronic
|
|
0.740 |
GeneticVariation
|
CLINVAR |
Use of direct sequencing for detection of mutations in the BCR-ABL kinase domain in Slovak patients with chronic myeloid leukemia.
|
21895409 |
2011 |
Myeloid Leukemia, Chronic
|
|
0.740 |
GeneticVariation
|
CLINVAR |
Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors.
|
19768693 |
2010 |
Myeloid Leukemia, Chronic
|
|
0.740 |
GeneticVariation
|
CLINVAR |
Mutations in ABL kinase domain are associated with inferior progression-free survival.
|
20367437 |
2010 |
Myeloid Leukemia, Chronic
|
|
0.740 |
GeneticVariation
|
BEFREE |
In 1 patient with lymphoid blast crisis of CML coexisting F359V and Y253F mutations were detected.
|
20010464 |
2009 |
Myeloid Leukemia, Chronic
|
|
0.740 |
GeneticVariation
|
BEFREE |
Dasatinib treatment can overcome imatinib and nilotinib resistance in CML patient carrying F359I mutation of BCR-ABL oncogene.
|
18436994 |
2008 |
Myeloid Leukemia, Chronic
|
|
0.740 |
GeneticVariation
|
BEFREE |
We conclude that (a) amino acid substitutions at seven residues (M244V, G250E, Y253F/H, E255K/V, T315I, M351T, and F359V) account for 85% of all resistance-associated mutations; (b) the search for mutations is important both in case of imatinib failure and in case of loss of response at the hematologic or cytogenetic level; (c) advanced-phase chronic myeloid leukemia and Ph+ ALL patients have a higher likelihood of developing imatinib-resistant mutations; and (d) the presence of either P-loop or T315I mutations in imatinib-treated patients should warn the clinician to reconsider the therapeutic strategy.
|
17189410 |
2006 |
Myeloid Leukemia, Chronic
|
|
0.740 |
GeneticVariation
|
CLINVAR |
High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib.
|
14745431 |
2004 |
Myeloid Leukemia, Chronic
|
|
0.740 |
GeneticVariation
|
CLINVAR |
Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.
|
12623848 |
2003 |